WeVote
Log In

Bill

Bill

SB 1357

Relating to a cancer clinical trial participation program.

89th Legislature (2025) Introduced by Tan Parker

SB 1357 establishes a Texas cancer clinical trial participation program to improve patient access to experimental treatments and advance oncology research through coordinated healthcare and research partnerships.

Referred to Health & Human Services
#cancer(s0658) #education--higher--healthinstitutions(i0237) #health--otherdiseases&medicalconditions(i0383) #research&development(s0135)
0
WeVote Research Nonpartisan
Bill Summary · SB 1357

Legislative bill overview

SB 1357 establishes a cancer clinical trial participation program in Texas, though specific program details are not yet publicly available given its early filing stage. The bill aims to facilitate patient access to cancer clinical trials, likely through coordination between healthcare providers, research institutions, and patients. This represents a state-level initiative to expand opportunities for cancer patients to participate in experimental treatments and contribute to medical research.

Why is this important

Cancer patients often lack information about or access to clinical trials that could offer new treatment options beyond standard care. A structured participation program could improve patient outcomes by connecting eligible individuals with appropriate trials while also advancing Texas-based cancer research and potentially attracting research funding and institutions to the state. This addresses both individual patient needs and broader public health infrastructure development.

Potential points of contention

  • Funding and implementation costs – Establishing and maintaining a statewide program requires resources; unclear whether funding comes from state budget, healthcare systems, or pharmaceutical partners
  • Patient recruitment and equity – Questions about how the program will ensure diverse participation and prevent targeting wealthier or better-connected populations while reaching underserved communities
  • Liability and informed consent – Defining responsibility if trial participants experience adverse effects and ensuring robust informed consent procedures in a state-managed context
  • Data privacy – How patient information will be collected, shared between institutions, and protected throughout the program

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.